Campath BLA For Chronic Lymphocytic Leukemia Has June User Fee Goal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium Pharmaceuticals and Ilex Oncology are hoping to launch their monoclonal antibody Campath (alemtuzumab) before the end of 2000 for treatment of B-cell chronic lymphocytic leukemia (CLL) in patients refractory to first- and second-line therapy.